title: The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.
abstract: To assess the relation between resistance to antiretroviral drugs for treatment of HIV-1 infection and virological response to therapy, results from 12 different studies were re-analysed according to a standard data analysis plan. These studies included nine clinical trials and three observational cohorts. The primary end-point in our analyses was virological failure by week 24. Baseline factors that were investigated as predictors of virological failure were plasma HIV-1 RNA, the number and type of new antiretroviral drugs in the regimen, and viral susceptibility to the drugs in the regimen, determined by genotyping or phenotyping methods. These analyses confirmed the importance of both genotypic and phenotypic drug resistance as predictors of virological failure, whether these factors were analysed separately or adjusted for other baseline confounding factors. In most of the re-analysed studies, the odds of virological failure were reduced by about twofold for each additional drug in the regimen to which the patient's virus was sensitive by genotyping methods, and by about two- to threefold for each additional drug that was sensitive by phenotyping.
authors.affiliation: Harvard School of Public Health, Boston, Mass., USA.
authors.forename: V
authors.initials: V
authors.lastname: DeGruttola
authors.forename: L
authors.initials: L
authors.lastname: Dix
authors.forename: R
authors.initials: R
authors.lastname: D'Aquila
authors.forename: D
authors.initials: D
authors.lastname: Holder
authors.forename: A
authors.initials: A
authors.lastname: Phillips
authors.forename: M
authors.initials: M
authors.lastname: Ait-Khaled
authors.forename: J
authors.initials: J
authors.lastname: Baxter
authors.forename: P
authors.initials: P
authors.lastname: Clevenbergh
authors.forename: S
authors.initials: S
authors.lastname: Hammer
authors.forename: R
authors.initials: R
authors.lastname: Harrigan
authors.forename: D
authors.initials: D
authors.lastname: Katzenstein
authors.forename: R
authors.initials: R
authors.lastname: Lanier
authors.forename: M
authors.initials: M
authors.lastname: Miller
authors.forename: M
authors.initials: M
authors.lastname: Para
authors.forename: S
authors.initials: S
authors.lastname: Yerly
authors.forename: A
authors.initials: A
authors.lastname: Zolopa
authors.forename: J
authors.initials: J
authors.lastname: Murray
authors.forename: A
authors.initials: A
authors.lastname: Patick
authors.forename: V
authors.initials: V
authors.lastname: Miller
authors.forename: S
authors.initials: S
authors.lastname: Castillo
authors.forename: L
authors.initials: L
authors.lastname: Pedneault
authors.forename: J
authors.initials: J
authors.lastname: Mellors
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003627:Data Interpretation, Statistical; D004352:Drug Resistance, Microbial / Q000235:genetics; D004359:Drug Therapy, Combination; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D010641:Phenotype; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors